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Abstract
Ischemic heart disease is the leading cause of death for women in the Western
hemisphere. Women with ischemic heart disease typically present to the emergency
department with acute coronary syndrome, and subsequently undergo coronary
angiography. In 66% of women, no evidence of obstructive disease is found, and current
standard of care recommends no further diagnostic testing. However, nonobstructive
diseases cannot be ruled out with coronary angiography alone and therefore are
frequently missed. This study will examine whether invasive physiological testing
with coronary angiography can impact multiple adverse cardiac events in adult
women. Using a prospective comparative effectiveness trial, we will compare the
occurrence of these events at one year in adult women that undergo coronary
angiography plus invasive physiological testing rather than standard of care. This study
may help improve diagnostic accuracy and inform disease-specific treatment for women
with nonobstructive coronary disease, as well as decrease healthcare utilization costs.
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Chapter 1 – Introduction
1.1 Background
For women in the United States, and worldwide, as well, cardiovascular diseases
(CVDs) remain the leading cause of death1-4. Yet despite this staggering fact, CVDs are
largely understudied in women and often thought of as primarily impacting men1, leaving
women out of critical research and a gaping hole in knowledge about how CVDs really
impact women5. This is due largely in part to the fact that women often present
differently from men with CVDs. While men present with the classic left-sided, crushing
chest pain radiating to the left shoulder or arm, women tend to have more atypical
symptoms such as dyspnea or weakness that can lead to a delayed presentation6-8. This
delayed presentation can be as little as hours to days to present to the Emergency
Department (ED), or even years later than men would typically present, and has been
somewhat attributed to the decrease of estrogen with age and estrogen’s analgesic
property, as well as reluctance to seek care for their symptoms or barriers to access1,5,9.
Additionally, women presenting with acute coronary syndrome (ACS) are often
underdiagnosed10. This is partially attributed to studies that have shown that the
diagnostic cutoff for troponin levels is too high for typically presenting women, as men
more often present with higher levels10. With this underdiagnosis, women are also less
likely to receive coronary angiography or pharmacological treatment than men are for
their ACS, leaving the etiology of their ACS both undiagnosed and untreated1,10. Patients
have even been falsely told that there was nothing wrong with their heart when in fact
further testing was not conducted to ensure this was true11.
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1.2 Statement of the Problem
When women are able to receive a coronary angiogram, they are more likely to
have nonobstructive disease (<50% stenosis)12-15. There are various causes for
nonobstructive disease that are not able to be determined from coronary angiography
alone, including but not limited to microvascular dysfunction and vasospastic angina12,1618

. Coming to the correct diagnosis is important for implementing an effective treatment

plan for patients, and yet the standard of care in current practice is to pursue no further
diagnostic testing after obstructive coronary artery disease is ruled out on coronary
angiogram, often resulting in women being falsely reassured that they do not have
coronary dysfunction when that may not be true19,20. With only a diagnosis of
nonobstructive disease and no further classification of disease, medical management is
less likely to be used than in their obstructive coronary disease counterparts, in which
there are evidence-based treatment guidelines including medications, revascularization,
and cardiac rehabilitation21. There is no consistency across institutions in treating
nonobstructive disease thanks in part to the lack of a well-classified diagnostic algorithm
and an overall lack of research on these diseases21,22.
Nonobstructive diseases have additionally been associated with higher rates of
adverse cardiac events including stroke, myocardial infarction, heart failure, and even
death, putting women disproportionately at risk for these adverse events and requiring
further follow up/healthcare burden9,21-23. According to the Women’s Ischemia Syndrome
Evaluation (WISE) study that has been conducted over the past 25 years, women with
nonobstructive disease have a 13% overall mortality rate24. Much of these adverse events
are in the setting of microvascular dysfunction, underscoring the importance of further
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research into these nonobstructive diseases24. One crucial step in this process is to
develop a diagnostic pathway for the various diseases that fall under the nonobstructive
umbrella.
In the recent Coronary Microvascular Angina (CorMicA) trial, Ford et al. utilized
an interventional diagnostic procedure in patients that were found to have ischemia and
nonobstructive disease on coronary angiography to determine if there was a subsequent
decrease in angina using the Seattle Angina Questionnaire25. They found that by
performing this interventional diagnostic procedure (which involves inserting a guidewire
to infuse adenosine and acetylcholine into the great vessels of the heart) they were better
able to diagnose nonobstructive diseases such as microvascular angina and vasospastic
angina and stratify treatment more appropriately for each diagnosis. This subsequently
led to improved angina and quality of life for patients that received this intervention25.
This study in addition to the WISE trial are pivotal steps in suggesting further diagnostic
workup for patient with nonobstructive disease to further classify the etiology of the
ischemia and filling the gap in research.

1.3 Goals and Objectives
The goal of this study is to evaluate if coronary angiogram with invasive physiologic
testing is a viable option for improving diagnostic phenotyping in women with acute
coronary syndrome and nonobstructive coronary dysfunction. We will accomplish this by
determining if coronary angiography with invasive physiologic testing compared to
historical data from Connecticut hospitals on the standard of care (coronary angiography
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alone) in women with ACS found to have nonobstructive coronary dysfunction impacts
the occurrence of MACE in the year following intervention.
The objectives of this study are to determine if coronary angiogram with invasive
physiologic testing can lead to improved diagnostic phenotyping and personalized
treatment strategies for women with ACS and nonobstructive coronary dysfunction,
therefore leading to decreased subsequent MACE. Secondarily, we will also evaluate if
coronary angiogram with invasive physiologic testing impacts each individual component
of MACE in the year following the intervention.

1.4 Hypothesis
We hypothesize that women over 18 years old with acute coronary syndrome who are
found to have no obstructive coronary artery disease on coronary angiography and who
subsequently undergo invasive physiologic testing to diagnose the mechanism of acute
coronary syndrome will have a statistically significant difference in occurrence of MACE
at one-year post-procedure as compared to historical data on those that undergo coronary
angiography alone and do not receive a definitive diagnosis.

1.5 Definitions
ACS: Acute Coronary Syndrome. The American Heart Association defines ACS as “an
umbrella term for situations where the blood supplied to the heart muscle is suddenly
blocked.” Patients will have a high clinical suspicion as well as a rise or fall in cardiac
markers (at least two consecutive cardiac troponins).
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MACE: Major Adverse Cardiac Events including recurrent angina pain, development of
heart failure, non-fatal infarction, presentation to the Emergency Department with
cardiovascular-related illness, admission to the hospital for cardiovascular-related illness,
percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG),
stroke, and all-cause mortality.
Nonobstructive Disease: <50% vessel obstruction visualized on coronary angiogram
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Chapter 2 – Review of the Literature
2.1 Introduction
An extensive review of the relevant literature was performed with help from the
Yale University School of Medicine librarians in July 2020 and from November 2020December 2020. The databases utilized were Pubmed, Ovid Medline, Scopus, and The
Cochrane Medical Library. Key search terms relating to our study population included
“acute coronary syndrome,” ACS, coronary, women, female, adult, sex, angina, “chest
pain,” and NSTEMI. Search terms related to our intervention included angiography,
“coronary angiogram,” adenosine, acetylcholine, “stratified therapy,” vasospasm,
microvascular, “microvascular angina,” MINOCA, and INOCA. Search terms relating to
our outcome included “major adverse cardiac events,” MACE, outcomes, and “one
year.” Finally, search terms related to our study type included “comparative
effectiveness” and prospective. Searches were limited to adults over 18 and studies
published in the last five years. Results were then screened for relevance to this study.

2.2 Review of Sex Differences in Coronary Artery Diseases
There is a generalized paucity of research on coronary artery diseases in women
that has only begun to rectify itself over the past few years. This is likely due in part to
the differing pathophysiology of coronary artery disease in women and the increased
likelihood of a nonobstructive diseases such as coronary microvascular dysfunction26,27.
In 2015, Pepine et al. called attention to this gap in the literature with a position paper.
They reference the Women’s Ischemia Syndrome Evaluation (WISE) study, which was a
prospective cohort of 936 women with angina or suspicion for ischemia that underwent
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coronary angiography, as the primary resource for data on nonobstructive disease in
women26. Their study made huge initial strides in the way of shrinking the gender gap in
research by conducting a study with only women participants over several years. Some of
their findings include that about 66% of women enrolled were found to have
nonobstructive coronary dysfunction and that for this group of women there was a yearly
risk of 2.5% that MACE would occur26 with a 5 year rate of MACE around 11%
(p<0.001)19.
Although the WISE study is certainly impactful, it is not without limitations, as
Pepine et al. point out, including a smaller sample size, selection bias including only
women that have access to healthcare, and recall bias by utilizing a self-reporting system
for MACE19,26. The WISE study was able to spur other studies, though, and similar
studies have replicated the same trend of women with ACS being more likely to have
nonobstructive diseases as well as worse outcomes26. Pepine et al. ended their position
paper with a call to action to address further knowledge gaps going forward including
being able to diagnose the mechanism behind ischemia as well as to stratify treatments
specific to underlying etiologies of disease with more clinical trials26.
In 2016, Kawamoto et al. published a review on sex differences in ACS to
evaluate the available data and studies at the time5. In this, they highlighted the very
prevalent disparities between women and men and the high mortality rate that heart
diseases pose to women, especially those with comorbidities and to minorities5. They also
ended their review with a call for more research so that better diagnostic modalities and
treatment algorithms can be developed for these high-risk populations5. This same year,
Mehta et al. published the first statement from the American Heart Association regarding
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myocardial infarction in women. They report that although mortality for women with
cardiovascular diseases has been declining in the past 15 years thanks to heightened
awareness, it is still killing women at higher rates than men1. They also highlight that
women are undertreated with current guidelines and have worse outcomes than their male
counterparts, further endorsing the need for more targeted research1.
There is also copious evidence that women presenting with ACS are less likely
than men to receive a coronary angiogram or to be diagnosed with any type of
myocardial infarction1,10. This is likely due in part to cardiac troponin (cTn) levels
varying between women and men and women being less likely to reach the threshold for
diagnosis10. However, in a 2018 study in Canada, researchers studied patients presenting
to the Emergency Department with chest pain to evaluate if cTn levels could account for
the differences in diagnosis and outcomes between men and women. They found that
even in men and women that presented with ACS and met the cTn criteria for a
myocardial infarction, women were still less likely to receive a coronary angiogram, be
diagnosed with a myocardial infarction, had higher rates of MACE, and were less likely
to be appropriately treated for their disease10. They do speculate that the higher rates of
MACE may be related to the higher rates of comorbid conditions in women, as the
difference did not persist and was no longer statistically significant when these conditions
were corrected for10. However, this was a novel study with a large sample size (7,272
participants) that showed statistically significant sex differences, and though not without
limitations such as lack of generalizability to patients without chest pain and use of coded
data, it is a step in the right direction and emphasizes that further research is warranted to
examine why these sex differences persist and what can be done about them10.

10

Conversely, in a 2018 study of patients with total obstructive coronary lesions
evaluating MACE after receiving PCI found that male participants had a decrease in
MACE over three years while female participants saw no change in MACE2. They
partially attribute this to complications that occurred during PCI being significant
predictors of 3-year mortality on multivariate Cox regression for women but not for
men2. This indicates that even for women with obstructive disease, the mortality risk is
higher after undergoing what is meant to be a lifesaving procedure, and continuing to
treat women the same way men are treated is not sustainable and instead may be putting
them at further risk. This is a German study that, while retrospective and not necessarily
representative of the overall female population, spanned nine years and had a large
sample size (2002 participants) making it important to consider. A similar study
conducted in the US in 2019 did not find any sex differences in outcomes post-PCI for
participants with total obstructive lesions7. This study, however, utilized a registry for
reporting outcomes, only had 1000 participants (196 of which were women), and only
evaluated MACE at 1 year as compared to the German study, subjecting this study to
potential biases and limitations7.
Another study of 21,375 participants in India published this year examined sex
differences in cardiovascular disease patients and found that women had more risk factors
including diabetes and hypertension, had a later presentation to care, and were less likely
to be treated28. They additionally had a 53% increased risk of in-hospital MACE
(adjusted RR 1.53, 95% CI 1.32-1.77, p<0.001) and a 39% increased risk of MACE 30
days afterwards (adjusted RR 1.39, 95% CI 1.65-2.07, p<0.001) than the men in the
study28. In terms of mortality, women were 67% more likely to die in the hospital
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(adjusted RR 1.67, 95% CI 1.42-1.97, p<0.001) and 48% more likely to die within 30
days (adjusted RR 1.48, 95% CI 1.29-1.70, p<0.001) than men28. This study found
significantly worse outcomes for women all around, even when adjusting for baseline
characteristics. Although India is a vastly different country than the United States, this
just further highlights this staggering issue worldwide. The ultimate goal for sex
differences in coronary dysfunction is to develop diagnostic algorithms that benefit
women specifically, as the current standard of care throughout the world is not working
well enough for women now8.

2.3 Review of Nonobstructive Coronary Dysfunction
The general consensus in the literature, and even from the European Society of
Cardiology and the American Heart Association/American College of Cardiology, is that
nonobstructive disease is considered to be <50% vessel obstruction with elevated cardiac
biomarkers (usually cTn)12-15. Another term that is often used in the literature is
MINOCA, or myocardial infarction with no obstructive coronary artery disease. The
specific nature of this terminology, though, implies there is a component of MI/ischemia
occurring, which is not the case for all patients presenting with acute coronary syndrome,
but is certainly one of the most dangerous diagnoses15. For the purposes of our study, we
will continue to refer to our participants as those with nonobstructive coronary
dysfunction rather than restricting them to the MINOCA umbrella.
The recent rise in nonobstructive coronary dysfunction, particularly in women, is
likely multifactorial. Not only do we have an aging population in which NSTEMIs are
more common than STEMIs, but also by relying more heavily on cTn as a biomarker of
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ischemic disease rather than creatinine kinase-myocardial isoenzyme (CK-MB), more
disease processes are being classified as NSTEMIs rather than unstable angina6,15,29. In
addition to this rise in prevalence is the theory that nonobstructive disease are more
dangerous than originally thought, and with this danger comes an increasing need to
further classify the underlying etiology9. In their 2018 review, Makarovic et al. proposed
to classify nonobstructive disease by whether they are ischemic (Type I) or nonischemic
(Type II) in which ischemic diseases are further differentiated as endothelium dependent
(1A), endothelium independent (1B), or vasoconstrictive (1C) and nonischemic diseases
are further differentiated as neurogenic afferent (2A), neurogenic efferent (2B), or
habitual (2C)9. This proposed classification system is another step in the right direction
and even suggests different clinical presentations patients may express, but ultimately is
not useful without effective means of diagnosis, again highlighting the need for further
studies proposing accurate diagnostic modalities.
In a recent statement from the American Heart Association, Tamis-Holland
(Chair) et al. published in 2019 a proposed clinical algorithm called the “Traffic Light”
Sequence to help diagnose nonobstructive disease that offers various diagnostic
modalities depending on clinical presentation15. This algorithm includes considering noncardiac causes of elevated cTn and nonobstructive disease as well as alternate diagnoses
such as obstructive disease, dissection, Takotsubo cardiomyopathy, and myocarditis15.
They recommend noninvasive techniques such as Echocardiogram or cardiac MRI if less
suspicious for MINOCA, but for nonobstructive coronary dysfunction such as coronary
vasospasm or microvascular disease, more invasive strategies are recommended
instead15. This proposed algorithm is one of the first of its’ kind, and it carries a lot of
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weight coming from the American Heart Association. It can help clinicians to make
important strides in getting to the root cause of coronary dysfunction and then prescribe
appropriate treatment regimens and improve overall outcomes15. Our proposed study
would be applying part of this algorithm as our participants would have a high suspicion
for nonobstructive dysfunction on presentation, being all women with ACS, and could
provide further evidence for widespread implementation of this diagnostic algorithm or
something similar.
This novel statement also suggests potential therapies for the variety of etiologies
that could be diagnosed if this diagnostic algorithm was implemented, a field which is
also in desperate need of further clinical trials as the diagnostic research is
progressing15,30. Some of their suggestions based on what research is currently available
include aspirin and another antiplatelet agent for plaque disruption, calcium channel
blockers for coronary vasospasm, and calcium channel blockers and beta blockers for
microvascular dysfunction15. The Women’s IschemiA Trial to Reduce Events in
NonObstructive CAD (WARRIOR) trial is a new study currently in progress that aims to
further examine the best treatment pathways for women with nonobstructive coronary
dysfunction31. This trial is multicenter, prospective, and randomized with a blinded
outcome evaluation, and is comparing intensive medical therapy with statins and
angiotensin converting enzyme inhibitors (ACE-I) or receptor blockers (ARB) to the
current standard of care on the occurrence of MACE31. Hopefully the results of this trial
will help guide treatment in women with nonobstructive coronary dysfunction going
forward.
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2.4 Review of Diagnostic Modalities for Nonobstructive Coronary Dysfunction
Although there is no true consensus on the best diagnostic modality for
nonobstructive coronary dysfunction, there have been more recent studies on noninvasive
techniques such as cardiovascular magnetic resonance (CMR), computed tomography
(CT), and functional stress testing8,32-34. Additionally, Positron emission tomography
(PET) myocardial perfusion imaging (MPI) can also quantify coronary flow reserve
(CFR) of coronary vessels and is thought to be useful in prognosis and risk assessment,
especially as more facilities are combining PET and CT8. These imaging techniques aim
to do a similar job as a more invasive testing procedure with the added benefits of being
less limited by cost and perhaps more accessible. However, for our study, the participants
we are recruiting would be receiving an invasive coronary angiogram regardless, and the
additional invasive procedure we propose would not add much time or effort to what is
already being done. Patients that do not require coronary angiogram initially may be
better served by these noninvasive techniques.
In the WISE study, one of the more invasive diagnostic modalities they tested was
coronary reactivity testing (CRT) in which acetylcholine was infused in various
concentrations into the coronary arteries (specifically the left anterior descending or
LAD) of patients with ACS and nonobstructive coronary dysfunction and pressures were
measured in the left ventricle and aorta to look for microvascular disease20,35-37. They
then examined subsequent adverse events and MACE, finding that only two participants
(0.7%) had serious in-procedure events of dissection from the doppler wire not requiring
intervention and a focal coronary spasm prior to acetylcholine infusion treated with
nitroglycerin20. Another two women (0.7%) had adverse events in procedure which were
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a transient air microembolism that resolved with supplemental oxygen and a deep vein
thrombosis (DVT) a month afterwards that resolved with anticoagulation20. As for
MACE in these participants, which included, death, MI, stroke, or hospitalization for
heart failure, there was a rate of 8.2% in the following five and a half years20. The low
rates of serious and general adverse events in-procedure and right afterwards is reassuring
for an invasive procedure in a high-risk population.
In the WISE trial, to discuss this first invasive intervention more specifically,
assessing microvascular reactivity with CFR was measured by injecting adenosine in two
increasing amounts into the coronary arteries and taking a ratio of peak velocity to rest
velocity with each infusion (CFR > 2.32 was considered normal)23. When examining
MACE with this technique, rates of MACE over 10 year follow-up were increased in
participants with a low CFR (p = 0.008 for 3-component MACE and p = 0.028 for 4component MACE) and low CFR levels independently, statistically significantly
predicted the 4-component MACE even when corrected for baseline characteristics (HR
1.06, 95% CI 1.004-1.12, p = 0.035)23. Although this trend of low CFR being a predictor
of MACE has been previously established, and that CFR is often lower in women38, this
study was able to replicate it with longer-term follow-up. The authors again reiterate that
although these procedures are invasive, they are fairly safe with low rates of
complications or adverse effects, making them a considerable option for going women
with ACS and nonobstructive coronary dysfunction23,39.
Another invasive technique used to further evaluate the underlying etiology of
nonobstructive coronary dysfunction in the WISE study is to infuse acetylcholine to
assess for vessel reactivity and coronary vasospasm40. They did this by infusing
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acetylcholine into the coronary arteries for two three-minute periods then measuring
blood flow, pressure, and vessel diameter to assess for changes23. With this technique, the
researchers found that decreases in coronary blood flow by 10% increased the mortality
risk by 23% (HR 1.23, 95% CI 1.04-1.45, p = 0.015), as well as a 16% increase in both 4component and 3-component MACE (HR 1.16, 95% CI 1.06-1.27, p = 0.001 and HR
1.16, 95% CI 1.05-1.28, p = 0.003 respectively)23. All this is to say that this invasive,
reasonably safe technique appears to be effective in identifying participants with
coronary arteries prone to vasospasm that puts them at higher risk for MACE. The
authors do reiterate here, though, that testing requires specific training and is not very
cost effective, despite its diagnostic effectiveness. Additionally, results here may be
skewed because even though coronary dysfunction was further characterized, because
there is no universal treatment algorithm for these types of diseases yet, many of the
participants went without treatment and this could have impacted the occurrence of
adverse outcomes as well23.

2.5 Review of Relevant Methodology
The following sections will review current literature and the methodology used
relevant to this proposed study.

2.5.1 Selection of Intervention
As previously discussed, while more research is being conducted on less invasive
testing recently, invasive testing such as the proposed additional physiologic testing after
coronary angiogram seems to be effective in further characterizing nonobstructive
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coronary dysfunction. Not only is this evident in the WISE trial, but another trial titled
the CorMicA trial that was conducted in 2018 utilized a similar intervention in both men
and women12,23. They called their intervention an “interventional diagnostic procedure”
in addition to coronary angiography which involved assessing the LAD coronary artery’s
coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and fractional
flow resistance (FFR) (to determine a lesion’s functional significance41) while infusing
adenosine to evaluate microvascular dysfunction, as well as evaluating for coronary
vasospasm while infusing acetylcholine12. They examined the effect of this on subsequent
angina using the Seattle Angina Questionnaire, finding that angina was improved in those
that received the procedure in their randomized controlled trial12. This study was another,
similar to the WISE study, that showed an invasive procedure that had a positive impact
on outcomes for its nonobstructive coronary dysfunction participants. As there are many
hospitals across the state of Connecticut with coronary angiography capability staffed by
very capable interventional cardiologists that perform similar interventions daily, we
chose to mimic our own intervention after Ford et al.’s in the CorMicA trial to build upon
the data they have already compiled.
Additionally, a study conducted by Ahmed et al. on the safety of FFR and IMR
measurements with adenosine found that adverse effects were self-limited and serious
events such as STEMI, NSTEMI, and dissection were exceedingly rare, reinforcing the
overall safety of our chosen procedure42. A study by Fearon et al. touted IMR as a widely
available quantitative, and easily reproducible diagnostic strategy and found IMR > 40 to
be stronger predictor of adverse outcomes43. This same trend was recognized in a trial by
Fahrni et al. in 201744. Garcia et al. advocated for the use of FFR and CFR together in
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tandem to get the best picture of what is happening in the coronary arteries, as we
propose to do in our study45.

2.5.2 Selection of the Outcome
Many of the studies we have previously discussed have evaluated MACE as their
outcome. While we are basing our intervention on the CorMicA trial, their primary
outcome is the Seattle Angina Questionnaire and only examined angina in patients12. By
using MACE, we can include angina along with other adverse outcomes patients with
ACS and nonobstructive coronary dysfunction are likely to have such as stroke,
healthcare utilization, and even death from a cardiovascular cause. This is also a hard
outcome that can be measured from hospital system EMR rather than a subjective
questionnaire filled out by the patient themselves and not as subject to recall bias. Other
studies that have chosen MACE as their primary outcome include a 2019 study in China
by Abdu et al. examining MI in MINOCA patients and a 2020 study by Dreyer et al.
examining Medicare patients with MINOCA compared to those with obstructive MIs46,47.
Both studies found that older patients with MINOCA had worse outcomes46,47. Other
studies using MACE as their outcome have found the opposite trend, that MINOCA
patients had lower rates of MACE than obstructive disease patients, such as one study in
Spain by Garcia-Blas et al. and another in Poland by Zandecki et al.48,49. Regardless,
though, using MACE as our primary outcome like many other studies have allows us to
compare and contrast results with others in the field to ultimately contribute to a wider
body of knowledge. Additionally, by breaking down each individual component of
MACE as our secondary outcome, we can also compare data to other studies that use

19

various combinations of MACE because MACE is defined slightly differently for each
specific study.

2.5.3 Selection of the Study Population
While several studies, including the CorMicA trial, recruited both men and
women for their studies, the general trend is that nonobstructive diseases
disproportionally impact women12. Even in the CorMicA trial, about 74% of all patients
were women12 and the nature of the WISE study was to recruit only women, as well. As
also previously stated, women and men have differing pathophysiology of disease, and by
recruiting solely women, who are also understudied as a whole, we can minimize any sex
differences that may have been playing a role in the outcomes of studies the recruited
both sexes. This also contributes to the novelty of this study as a whole, being that there
are so few studies that only recruited women.
As far as choosing baseline characteristics for our study population, we chose
many that were similar to those in the CorMicA study such as age, medication usage,
comorbid conditions such as diabetes and dyslipidemia, smoking status, and BMI. We
also added some of our own that we thought may be interesting or potentially
contributory and would need to be controlled for in multivariate analysis such as
psychosocial factors, menopausal status, marital status, and prior therapies12. Many of
these baseline characteristics were also collected in other studies such as the WISE
study19,23,50.

2.5.4. Selection of Study Type
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While much of the current literature consists of randomized clinical trials or
cohort studies, we decided to go in a different direction and make our study a
comparative effectiveness trial. By using this type of trial, we are able to rely on
historical data from the hospitals we choose as our “control group” and enroll every
eligible participant into the intervention we are proposing51. This eliminates the need for
any blinding and helps us to achieve the appropriate sample size and power within the
year-long time frame. This type of study also contributes to the novelty of our research,
as in the literature searching, we were unable to find other studies that were conducted
this way for female patients with nonobstructive coronary dysfunction. The closest study
found was one by Kishi et al. in 2020 that examined the relationship between plaque
burden in coronary arteries evaluated cy cardiac CT and MACE that utilized a
comparative effectiveness study design52. They found success through achieving
statistical significance in their several of their results with this model and its feasibility of
comparing a novel intervention to the current standard of care, just as we propose to do52.

2.7 Conclusion
Overall, there are very clear gaps in the literature as far as nonobstructive
coronary dysfunction in women. Women as a whole are understudied in this field, as well
as more likely to have nonobstructive disease rather than obstructive. Nonobstructive
diseases additionally require diagnostic modalities that are not only accessible and
feasible, but also that are effective enough to further characterize the underlying
mechanism of disease so that patients can get appropriate treatment which should, in turn,
improve outcomes such as MACE. The proposed study aims to do just that,
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implementing additional invasive physiologic testing for women with ACS that are likely
to have nonobstructive disease in hospitals across Connecticut to determine if there is an
impact in MACE going forward.
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Chapter 3 – Study Methods
3.1 Study Design
The proposed study will be a multicenter, single-arm, prospective comparative
effectiveness clinical trial. We will target hospitals in the state of Connecticut that have
coronary angiography capability by working with the states’ two largest healthcare
systems, Yale New Haven Health and Hartford Healthcare. These hospitals would
include Yale New Haven Hospital, Greenwich Hospital, Bridgeport Hospital, Lawrence
and Memorial Hospital, and Westerly Hospital within the Yale New Haven Health
System, as well as Hartford Hospital, Backus Hospital, The Hospital of Central
Connecticut, St. Vincent’s Hospital, and Windham Hospital within the Hartford
Healthcare System. Because this is a comparative effectiveness trial, we would enroll
every patient able to give informed consent and meeting inclusion criteria into the
intervention and compare outcomes with historical data on MACE rates from the WISE
trial for women that underwent coronary angiography alone without further physiologic
testing19. The total proposed timeline for the study would be 24 months with an 11-month
recruitment period and 12-month follow-up period to assess for occurrence of MACE.
Hospital Electronic Medical Record (EMR) system will be used to monitor for MACE in
the following year. Both hospital systems use Epic for their EMR.

3.2 Study Population and Sampling
Because women are frequently left out of clinical trials and the evidence-based
medicine is tailored to male participants, our study would solely recruit women. The
study population would include women over the age of 18 presenting to Connecticut
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hospitals (with coronary angiography plus invasive physiologic testing capability) with
acute coronary syndrome and found to have nonobstructive disease on coronary
angiogram. We will sample using convenience sampling so that any woman coming
through the hospital doors with acute coronary syndrome will be recruited, contingent
upon their initial coronary angiogram results showing nonobstructive disease. Including
all hospitals from the two largest health systems in Connecticut that have coronary
angiogram capability increases the likelihood that we will have a representative sample
for adult women in the state of Connecticut. These 10 hospitals are spread throughout the
state, and if women with acute coronary syndrome presented to a smaller hospital within
the same system, they would need to be transferred to a hospital with coronary
angiography capability regardless, so these women would be accounted for as well.
Additionally, the nature of a comparative effectiveness study is that every woman with
the potential to be included will have the opportunity to be included, as the “control
group” is historical data from prior patients at each participating hospital, making the data
more generalizable than in a randomized controlled trial which can be subject to internal
bias. Women will be excluded from the study if they are found to have non-cardiac
angina, Takotsubo cardiomyopathy, or an ST-elevation myocardial infarction (STEMI).

3.3 Subject Protection and Confidentiality
Prior to the beginning of the study, institutional review board (IRB) approval will
be obtained through the Yale University School of Medicine. The procedure described in
section 100 PR.1 Review by a Convened IRB will be followed while submitting an
application. This application will include a detailed protocol, a plan and materials for
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recruiting, consent forms, Health Insurance Portability and Accountability Act (HIPAA)
forms, and a funding application. Consent forms (Appendix 1) will be given at the time
of recruitment on presentation to the Emergency Department to either the participant or
their healthcare proxy with clearly outlined study protocols as well as any potential
benefits and risks for participating in the study. While it may be challenging to obtain
informed consent in an acute setting, the patient will already be consenting for a coronary
angiogram to be performed, so we would come in afterwards to explain the additional
testing and to answer any questions or concerns participants may have. All patient data
will be stored on an encrypted server and de-identified of protected health information
where possible, closely following all HIPAA guidelines.
Because our study has the potential to include pregnant patients and those of
childbearing age, extra precautions will be taken to protect this vulnerable population.
We will follow section 330.1 Requirements for Approval of DHHS-funded Biomedical or
Behavioral Research Involving Pregnant Women or Fetuses to do so, as it is important to
include potentially pregnant patients in our study population because MACE may cause
significant harm to both mother and fetus, and the goal of this study is for our
intervention to impact subsequent MACE. Additionally, the risks associated with a
woman experiencing MACE outweigh those of performing additional physiologic testing,
making it ethical to include these women in the study population.

3.4 Recruitment
By utilizing convenience sampling, we will recruit every adult woman over age
18 that meets inclusion criteria presenting with ACS to the aforementioned Connecticut
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hospitals with coronary angiography capabilities. Participants will be consented prior to
coronary angiogram and will remain in the study to receive the additional physiologic
testing if they are found to have nonobstructive disease in their major coronary arteries. If
a participant presents with a STEMI on EKG or is found to have obstructive coronary
artery disease, Takotsubo cardiomyopathy, or a non-cardiac cause of ACS, they will also
be removed from the study population and will not receive the intervention.

3.5 Study Variables and Measures
The intervention will be performing coronary angiogram plus invasive
physiologic testing of the left anterior descending artery (LAD). The invasive physiologic
testing involves inserting a pressure wire to measure coronary reserve flow (CRF), index
of microcirculatory resistance (IMR) and fractional flow reserve (FFR) while infusing
adenosine (to assess for functionally obstructive epicardial disease and microvascular
dysfunction) and acetylcholine (to detect coronary vasospasm). This intervention is
described in more detail by Ford et al. for the CorMicA trial, and we will be modeling
our intervention after theirs12.
The primary endpoint for our study will be occurrence of MACE at one year after
the invasive physiologic testing is performed. This is a dichotomous variable, as
participants will either have MACE occur, or they will not. Secondary outcomes will
include the median number of each individual MACE component that occurs over one
year to examine each component on its own as compared to any MACE as a whole.

3.6 Blinding
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Our study does not have a control group and will instead be comparing the
outcomes of our participants to historical data on adult female patients that presented
with ACS, received a coronary angiogram, and was found to have nonobstructive disease
from each participating hospital. Due to the lack of a control group, every participant will
receive the intervention and therefore will not need to be blinded to it. Additionally,
researchers and those evaluating the primary and secondary outcomes will not need to be
blinded to the intervention the participant received, either, as all participants received the
same intervention.

3.7 Adherence
Adherence for our study primarily relies upon the training of qualified
interventional cardiologists to perform the additional invasive physiologic testing while
participants are undergoing coronary angiogram. We will target interventional
cardiologists at participating Connecticut hospitals that have copious experience
performing coronary angiograms and train them in the procedure before the recruitment
period, so they are comfortable performing it for the study itself. Each provider will be
required to attend a day-long training session, for which they will be compensated for
their time, where they will be educated on the potential benefits of the procedure and all
other study details, as well as given the opportunity to practice in a simulation. The
invasive physiologic testing is at a similar level of complexity as a typical coronary
angiogram, so it should not take the providers very long to feel comfortable performing
it. We will also have a researcher observe the first two procedures each provider
performers to assure consistency.
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As far as adherence for the participants, this is a one-time procedure, so the main
factor will be reporting the occurrence of MACE, or any adverse effects experienced in
the year following the procedure. As MACE are often events that would cause
participants to seek healthcare53, we can primarily monitor this through hospitals’ EMR.
Additionally, each participant will be given a researcher’s contact information to report
any occurrence of MACE, and researchers will be instructed to reach out to each
participant monthly by phone and/or email (by participant preference) to ask if MACE
has occurred, and to remind them what MACE consists of.

3.8 Monitoring of Adverse Events
In the CorMicA trial, there were very few adverse events recorded as a result of
the intervention, and ones that did occur were considered minor or easily reversible12.
The immediate adverse effects that we will need to monitor for during the procedure
would be persistent atrial fibrillation, and paroxysmal atrial fibrillation secondary to
acetylcholine. In the CorMicA trial, transient bradycardia and sinus pauses were not
considered adverse events, but rather expected physiologic reactions to the procedure12.
In the event that atrial fibrillation persisted and did not self-resolve within 30 minutes as
occurred in the CorMicA trial for one patient, the interventional cardiologist would be
advised to perform cardioversion with intravenous amiodarone while still in the cardiac
catheterization lab to revert the patient back to sinus rhythm, which was successful in the
CorMicA trial12.
In the WISE trial, there were also very few adverse events. They reported one
participant with a dissection from doppler wire insertion that did not require intervention,
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one participant with a focal spasm prior to the invasive physiologic testing that resolved
with nitroglycerin, one participant with a transient air microembolism that resolved with
supplemental oxygen, and one participant that developed a DVT a month after the
procedure that was effectively treated with anticoagulation20. These are all very low risk
of occurrence, and all amenable to treatments that any cardiac catheterization lab would
have at their disposal and that the interventional cardiologists would be capable of
administering.
Additionally, the nature of our outcome (MACE) is that they are adverse
outcomes in and of themselves. However, these outcomes are associated with patients
with acute coronary syndrome and nonobstructive coronary dysfunction in general and
may or may not be a direct result of our intervention20,46,47. Therefore, like any patient
undergoing coronary angiogram, we will encourage our participants to both seek urgent
medical attention in the setting of MACE occurring, as well as to later report this event to
a researcher. As previously stated, we will also have researchers reaching out to
participants monthly in addition to reviewing the EMR to assure we are aware of any
occurrence of MACE.

3.9 Data Collection
Data collection will occur continuously throughout this study. When participants
are enrolled in the study (or soon after the intervention, depending on timing and urgency
of coronary angiogram) baseline characteristics (detailed below) will be recorded. To
collect data on our primary outcome, participants will need to give permission for us to
view their EMR to monitor for the occurrence of MACE in the year following the
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intervention. We will also have researchers reach out monthly to the participants by
phone or email to assess for occurrence of MACE. The researcher will be required to fill
out the Participant MACE Form (Appendix 2) for each participant during these monthly
check-ins and evaluation of the EMR. All data collection information with be recorded on
encrypted servers. If at any time a participant wishes to withdraw from the study, their
associated information and data will be permanently deleted.

3.10 Sample Size Calculation
To calculate sample size for this comparative effectiveness trial, we will be
utilizing data from the WISE study and the Power and Sample Size Calculator provided
online by the Department of Biostatistics at Vanderbilt University19. From the WISE
study, their primary composite endpoint was cardiovascular events including MI, and
hospitalization for heart failure, stroke, or cardiac mortality which is similar to our
proposed MACE outcome19. They found that about 2% of the asymptomatic (control)
group met the primary composite endpoint while the symptomatic group was split into
normal coronary arteries and nonobstructive coronary artery disease for which 8% and
16% respectively met the primary composite endpoint19. To group these two symptomatic
groups together, we found that 8% of 318 participants with normal coronary arteries is
about 25 participants and 16% of 222 participants is about 35 participants, so added
together, 60 of 540 participants or about 11% of symptomatic patients met the primary
composite endpoint. We then calculated the sample size based on a power of 0.80 and a
Type I (alpha) error of 0.05 estimating that the probability of the outcome for a control
participant (p0) to be about 2% and the probability of the outcome for an experimental
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participant (p1) to be about 11%. This gives us a sample size of 117 participants to reach
this statistical power and Type I error. Detailed images and information regarding our
sample size calculation can be found in Appendix 3.

3.11 Statistical Analysis
Baseline characteristics (Table 1) for each participant that will be reported and
analyzed will include age, comorbid conditions (history of CVD or stroke, diabetes,
dyslipidemia, hypertension, severe COPD, overweight/obesity, or history of pregnancy
complication such as hypertension, premature delivery, gestational diabetes, or
preeclampsia), current medications (including statins, antihypertensives, antiplatelets,
anti-ischemics, or cholesterol-lowering), cardiovascular risk factors (such as smoking),
prior therapies (percutaneous coronary intervention or stents placed in the coronary
arteries), psychosocial factors (such as perceived stress evaluated by the Perceived Stress
Scale (PSS), depression evaluated by the Patient Health Questionaire-9 (PHQ-9), anxiety
evaluated by the General Anxiety Disorder-7 (GAD-7), household income, food security,
housing security, or transportation security), marital status, and menopause status.
Dichotomous, categorical, and ordinal variables, such as comorbid conditions,
medications, cardiovascular risk factors, prior therapies, psychosocial factors, marital
status, and post-menopausal status will all be analyzed as proportions. Continuous
variables including age is assumed to be normally distributed and will be analyzed as a
mean with a standard deviation.
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Characteristic

Type of Variable

Age

Continuous

Comorbid Conditions – history

Dichotomous

Number of Study Participants

of CVD or stroke, diabetes,
dyslipidemia, hypertension,
premature delivery, gestational
diabetes, preeclampsia
Medications – statins,

Dichotomous

antihypertensives, antiplatelets,
anti-ischemics, cholesterol
lowering
Cardiovascular Risk Factors (i.e.

Dichotomous

smoking)
Prior Therapies (i.e.

Dichotomous

PCI/stenting)
Psychosocial Factors –

Categorical – Ordinal (stress,

perceived stress, depression,

depression, anxiety, income)

anxiety, household income, food

Dichotomous (food, housing,

security, housing security,

transportation security)

transportation security
Post-menopausal

Dichotomous

Marital Status

Categorical - Nominal

Table 1. Baseline Characteristics of enrolled participants
The primary outcome, MACE, is a dichotomous variable and will be analyzed as
a proportion using a Chi-square test for bivariate analysis. To consider any potential
confounding effects of baseline characteristics as well as differences in care patterns by
hospital, we will employ a hierarchical multivariate analysis using a logistic regression.
The secondary outcomes will be the median number of each individual MACE
component (recurrent angina pain, development of heart failure, non-fatal infarction,
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presentation to the Emergency Department with cardiovascular-related illness, admission
to the hospital for cardiovascular-related illness, repeat PCI, CABG, stroke, and all-cause
mortality) that occurs over the one-year, post-intervention period and these are
continuous, not normally distributed variables. They will be analyzed as means with
standard deviations using a Student t-test. Significance will be defined as p<0.05.

3.12 Timeline and Resources
The timeline for this study will be a total of 24 months. After receiving IRB
approval, we will aim to begin the study in January 2022. During the first month, we will
properly train the interventional cardiologists that will be performing the invasive
physiologic testing at each participating Connecticut hospital. There will be a day-long
training at each hospital involving an overview of the study protocol, as well as a
summary of potential benefits and adverse outcomes, followed by a question-and-answer
session. There will then be an opportunity to practice the intervention through a virtual
simulation. These clinicians will all be familiar with typical coronary angiogram, and
because the procedure itself (infusing into and taking measurements of coronary arteries
using a guidewire) is similar to standard practice, the one-day training period should be
sufficient. However, we will have a researcher observe the first two sessions each
provider conducts with study participants, as well as one subsequent random session, to
assure consistency and that there are no further questions or clarifications. After this first
month of training, we will begin the recruiting period for the next 11 months, cutting off
enrollment at December 31, 2022 so as to allow for the full year of follow-up to assess
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for the occurrence of MACE. From January 1, 2023-December 21 2023 there will be
follow-up to assess for the primary and secondary outcomes.
Relevant personnel will include a principal investigator to oversee all areas of the
study. Additionally, we will need one research assistant assigned to each of the 10
participating Connecticut hospitals respectively. They will be in charge of helping
educate the interventional cardiologists prior to enrollment, the actual enrolling and
consenting of participants at the beginning of the study, and monthly follow-up with
patients and their EMR after the intervention to assess for occurrence of MACE. Lastly,
there will be one physician assistant student assigned to fill in any gaps in data collection
and to assist in statistical analysis and the writeup of the study afterwards.
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Chapter 4 – Conclusion
4.1 Advantages and Disadvantages
This study has several strengths. Through the nature of a comparative
effectiveness trial with every enrolled participant receiving the intervention and by
targeting the two largest health systems in the state of Connecticut, I believe we will be
reaching a large, diverse sample that is representative of the target population. This also
means that every participant that enrolls has the opportunity to achieve the potential
benefits of the additional invasive physiologic procedure. All of these factors make our
study highly generalizable. Additionally, as a one-time procedure, there is minimal
follow-up required for participants other than reporting if MACE occurs within the year
after the procedure, which can also be cross-checked using each hospital system’s EMR.
This decreases the likelihood that patients will be lost to follow-up as can be the case in
studies that require more patient participation throughout the following year.
Despite the many strengths, this study is not without limitations. One limitation of
this study is the cost. While the goal of this intervention is to decrease adverse outcomes
in the long-term for patients, which may result in less healthcare utilizations and saving
money in that respect later, the up-front costs will be high. Firstly, we will need to train
the interventional cardiologists performing the intervention and compensate them for
their time, as well as make sure each cardiac catheterization lab has access to the proper
tools and materials necessary for the intervention. We also need to compensate 10
research assistants (one for each hospital site) and the primary investigator for the twoyear duration of the study. This is important research, though, that has the potential to
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have a large, lasting impact on many patients, and with the proper time to apply for grant
funding, we will be able to fund this study.
Another potential limitation is obtaining informed consent in an acute
environment. Although we are excluding patients with STEMIs that need to go to the
cardiac catheterization lab urgently, we are recruiting patients that are in the ED for ACS
and this can be a stress-inducing environment for patients and family members alike.
However, as mentioned in Chapter 3, patients that qualify for our study will already be
consenting to receive a coronary angiogram while in the ED regardless, and our
researchers will be giving potential participants all study details including all known
potential risks and benefits. They will also be sure to answer all questions and concerns
the participant or healthcare proxy may have prior to enrollment to ensure they have all
the information required to make an informed decision to participate or not. If at any time
the participant chooses to leave the study after consenting, their information will be
removed from encrypted servers, and they can be assured that they will continue to
receive high quality care as per usual.

4.2 Clinical and Public Health Significance
This study has the potential to make a real difference, not just in the field of
cardiology, but in clinical practice as a whole. As previously mentioned, CVDs are still
the greatest cause of mortality for women across the world, and nonobstructive coronary
dysfunction is more and more frequently the underlying cause1-3,12-15. In recent studies,
invasive physiologic testing with acetylcholine and adenosine infusion into the coronary
arteries to assess for microvascular dysfunction or coronary vasospasm, like we propose

42

to implement here, has shown to be a safe, effective method of further characterizing the
diagnosis of nonobstructive coronary dysfunction23. For many patients, a diagnosis can
be life changing. Not only is coming to the correct diagnosis a potential answer to what is
causing the patient’s symptoms, but it is also a critical step in getting the proper treatment
for the underlying etiology of disease. With disease-specific treatment, we can impact
overall outcomes for our patients, which can lead to less utilization of the healthcare
system and decreased costs because adverse outcomes such as MACE are frequent
reasons patients need to seek healthcare. If we can train interventional cardiologists
across the country to perform this extra procedure while already doing a coronary
angiogram in the absence of obstructive disease, women in every state could have
decreased rates of MACE, including preventing unnecessary deaths. Admission to the
hospital is a bad prognostic sign, and should be avoided where possible54-56.
Providers in any field are likely to come across these patients, and with sound,
evidence-based research like this proposed study to back up proposed diagnostic
algorithms such as Tamis-Holland et al.’s “Traffic Light” Sequence15, providers can feel
confident in recognizing the signs symptoms of ACS with a potential nonobstructive
etiology and knowing what type of testing to order or referral to make. This study can
also lay a strong foundation for further research in disease-specific treatment algorithms
for nonobstructive coronary dysfunction, which is another area of up and coming
research that needs more clinical trials in the future.
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Appendix 1: EFIC Consent Form
COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A
RESEARCH STUDY
YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL
Study Title: Coronary angiogram plus invasive physiologic tests in women with
nonobstructive coronary dysfunction
Principal Investigator (the person who is responsible for this research): Megan
McCauley
Phone Number: (413) 464-3510
Research Study Summary:
•
•

•

•

•

•

We are asking you to continue being a part of our research study.
The purpose of this research study is to determine whether coronary angiogram
plus invasive physiologic testing for women with acute coronary syndrome found
to have nonobstructive coronary dysfunction results in a decreased occurrence of
major adverse cardiac events (MACE) in one year.
Study procedures will include: Everyone in this study will receive a coronary
angiogram and if there is less than 50% obstruction of the blood vessels in your
heart by plaque buildup, you are considered to have “nonobstructive” coronary
disease. You will then receive an additional invasive physiologic procedure that
involves inserting a guidewire to infuse adenosine and acetylcholine to assess for
any abnormalities and measuring pressures in the vessels. If you are found to have
more than 50% obstruction, you will not qualify to participate in this study and
will not receive the additional physiologic testing or be asked to follow-up with
us. We will permanently delete all of your information from our encrypted
servers.
There risks to participating in this study are minimal and reversible. Because it is
a one-time procedure, the risks often happen at the time of the procedure and
include atrial fibrillation that is reversible on its own or atrial fibrillation that
requires a very effective medication called amiodarone to reverse. Very few
participants in prior studies experienced this adverse effect.
Taking part in the continuation of this study is your choice. You can choose to
take part, or you can choose not to take part in this study. You can also change
your mind at any time. Whatever choice you make, you will not lose access to
your medical care or give up any legal rights or benefits.
If you are interested in learning more about the study, please continue reading, or
have someone read to you, the rest of this document. Take as much time as you
need before you make your decision. Ask the study staff questions about anything
you do not understand. Once you understand the study, we will ask you if you
wish to continue to participate; if so, you will have to sign this form.
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Why is this study being offered to me?
We are asking you to take part in a research study because you are an adult female that
came to the Emergency Department (ED) and your ED provider believes you are
having an Acute Coronary Syndrome requiring a coronary angiogram.
Who is paying for the study?
Yale School of Medicine Physician Associate Program
What is the study about?
The purpose of this study is to evaluate if coronary angiogram with invasive physiologic
testing is a viable option for improving diagnostic classification in women with acute
coronary syndrome and nonobstructive coronary dysfunction. You have already
consented to receive a coronary angiogram as part of your diagnostic workup for your
acute coronary syndrome. The physician performing the angiogram will run a few extra
tests if your coronary arteries show <50% obstruction. This includes infusing
acetylcholine and adenosine into your coronary arteries and measuring pressures and
taking measurements to observe for microvascular dysfunction or coronary vasospasm.
What are you asking me to do and how long will it take?
You are being asked to participate in this study because you are an adult female that met
enrollment criteria by presenting to the ED with Acute Coronary Syndrome and are being
referred for urgent coronary angiogram. While receiving a coronary angiogram in the
cardiac catheterization lab, if your coronary arteries have from 0-49% obstruction with
plaque, you are considered to have “nonobstructive coronary dysfunction” and qualify to
continue participating in the study. While you are still in the catheterization lab under
anesthesia, the interventional cardiologist that has been training in this procedure will
perform additional invasive physiologic testing. This testing has been shown to be very
safe with low risks of complications or adverse effects and has not increased hospital stay
time.
The additional invasive physiologic testing specifically involves inserting a pressure wire
through your radial artery into your Left Anterior Descending (LAD) coronary artery to
measure coronary reserve flow (CRF), index of microcirculatory resistance (IMR) and
fractional flow reserve (FFR) while infusing adenosine (to assess for functionally
obstructive epicardial disease and microvascular dysfunction) and acetylcholine (to detect
coronary vasospasm).
As this is a one-time procedure, the follow-up required would be reporting and Major
Adverse Cardiac Events (MACE) that may or may not occur over the next year. MACE
includes recurrent angina pain, development of heart failure, non-fatal infarction,
presentation to the Emergency Department with cardiovascular-related illness, admission
to the hospital for cardiovascular-related illness, percutaneous coronary intervention

46

(PCI), coronary artery bypass grafting (CABG), stroke, and all-cause mortality. You
would give us access to your online medical record to determine if any of these events
occurred to you and if so, how many. Additionally, you would allow a research assistant
to reach out to you monthly to assess if one of these events occurred to you in the past
month but did not cause you to seek medical care.
What are the risks and discomforts of participating?
There are minimal side effects associated with this additional invasive physiologic
procedure reported in prior studies. Most reported were minor or easily reversible while
still in the cardiac catheterization lab.
Potential Adverse Events Reported from Prior Studies:
One participant experienced a dissection (or false passage) of their coronary artery from
pressure catheter insertion. This did not require any intervention as blood flow was not
detrimentally impacted.
Another participant experienced a focal spasm of their coronary artery after the coronary
angiogram and prior to the invasive physiologic testing that resolved soon after with the
administration of intravenous nitroglycerin.
One other participant experienced transient air microembolism that resolved with
supplemental oxygen.
One more patient developed a deep vein thrombosis 1 month after the procedure that
resolved with guideline-approved anticoagulation.
A few patients also experienced transient atrial fibrillation that self-resolved. One patient
had atrial fibrillation that persisted >30 minutes that resolved when give intravenous
amiodarone while still in the cardiac catheterization lab.
These are the only risks we are currently aware of, but there is always a possibility of
unforeseen risks.
Reproductive risks:
There have been no reports of harm to pregnant patients or their babies from this
intervention, and the risks posed by MACE to the general population are considered
worse, so we allow pregnant patients to be a part of this study if they so choose.
How will I know about new risks or important information about the study?
We will tell you if we learn any new information that could change your mind about
taking part in this study.
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How can the study possibly benefit me?
This study may or may not help you, but we hope it will decrease your risk for
subsequent MACE in the future. Less risk for MACE means less need to seek healthcare,
and less cost for your due to seeking this healthcare. We also hope that this will give us
further insight into what is causing your Acute Coronary Syndrome and Nonobstructive
coronary dysfunction so we can correctly diagnose you and better treat the cause.
How can the study possibly benefit other people?
The benefits to science and other people may include implementing and making
accessible this additional testing in hospitals across the country so that others may receive
a clear diagnosis for their nonobstructive coronary dysfunction and also receive the best
treatment possible so they also have decreased risks of MACE.
Are there any costs to participation?
You will not have to pay for taking part in this study.
Will I be paid for participation?
You will not be paid for taking part in this study.
How will you keep my data safe and private?
We will keep all information we collect about you completely confidential. We will only
share it with others if you agree to it or when we have to do it because U.S. or state law
requires it. We will keep all data related to your care password protected in a secure
database.
When we publish the results of the research or talk about it in conferences, we will not
use your name or other identifying information, such as your address or date of birth. We
will also not share information about you with other researchers for future research.
What Information Will You Collect About Me in this Study?
The information we are asking to use and share is called “Protected Health Information.”
It is protected by a federal law called the Privacy Rule of the Health Insurance Portability
and Accountability Act (HIPAA). In general, we cannot use or share your health
information for research without your permission. If you want, we can give you more
information about the Privacy Rule. Also, if you have any questions about the Privacy
Rule and your rights, you can speak to Yale Privacy Officer at 203-432-5919.
The specific information about you and your health that we will collect, use, and share
includes:
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•
•

Research study records
Medical and laboratory records of only those services provided in connection with
this Study.

•
•
•
•

The entire research record and any medical records held by your other
healthcare providers
Records about phone calls made as part of this research
Records about your study visit
Information obtained during this research regarding
▪ Records about your medical condition ▪ Records about the study intervention

How will you use and share my information?
We will use your information to conduct the study described in this consent form.
We may share your information with:
•
•

The U.S. Department of Health and Human Services (DHHS) agencies
Representatives from Yale University, the Yale Human Research Protection
Program and the Institutional Review Board (the committee that reviews,
approves, and monitors research on human participants), who are responsible for
ensuring research compliance. These individuals are required to keep all
information confidential.

•

The U.S. Food and Drug Administration (FDA) This is done so that the FDA can
review information about catheter, guidewire, and pressure-wire involved in
this research. The information may also be used to meet the reporting
requirements of drug regulatory agencies.
The study sponsor or manufacturer of study drug/device
Co-Investigators and other investigators
Study Coordinator and Members of the Research Team
Data and Safety Monitoring Boards and others authorized to monitor the conduct
of the Study

•
•
•
•

We will do our best to make sure your information stays private. But, if we share
information with people who do not have to follow the Privacy Rule, your
information will no longer be protected by the Privacy Rule. Let us know if you
have questions about this. However, to better protect your health information,
agreements are in place with these individuals and/or companies that require that
they keep your information confidential.
Why must I sign this document?
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By signing this form, you will allow researchers to continue to use and disclose
your information described above for this research study. This is to ensure that the
information related to this research is available to all parties who may need it for
research purposes. You always have the right to review and copy your health
information in your medical record.
What if I change my mind?
The authorization to use and disclose your health information collected during
your participation in this study will never expire. However, you may withdraw or
take away your permission at any time. You may withdraw your permission by
telling the study staff or by writing to Megan McCauley at the Yale University,
New Haven, CT 06520.
If you withdraw your permission, you will not be able to stay in this study but the
care you get from your doctors outside this study will not change. No new health
information identifying you will be gathered after the date you withdraw.
Information that has already been collected may still be used and given to others
until the end of the research study to ensure the integrity of the study and/or study
oversight.
What if I want to refuse or end participation before the study is over?
Taking part in this study is your choice. You can choose to take part, or you can
choose not to take part in this study. You also can change your mind at any time.
Whatever choice you make, you will not lose access to your medical care or give
up any legal rights or benefits.
We would still treat you with standard therapy or, at your request, refer you to a clinic or
doctor who can offer this treatment. Not participating or withdrawing later will not harm
your relationship with your own doctors or with this institution.
To withdraw from the study, you can call a member of the research team at any time and
tell them that you no longer want to take part.
The researchers may withdraw you from participating in the research if necessary. This
may occur if you are discovered to not meet enrollment criteria, such as if you are:
under 18 years of age, a prisoner, or ward of state.
What will happen with my data if I stop participating?
If you decide to stop participating in the study, all data and images associated with your
name will be deleted from our database.
Who should I contact if I have questions?

50

Please feel free to ask about anything you don't understand.
If you have questions later or if you have a research-related problem, you can call the
Principal Investigator at (413) 464-3510.
If you have questions about your rights as a research participant, or you have complaints
about this research, you call the Yale Institutional Review Boards at (203) 785-4688 or
email hrpp@yale.edu.
Authorization and Permission
Your signature below indicates that you have read this consent document and that you
agree to be in this study.
We will give you a copy of this form.
_____________________________

_____________________________

_______

Participant Printed Name

Participant Signature

Date

_____________________________

_____________________________

_______

Person Obtaining Consent

Person Obtaining Consent

Date

Printed Name

Signature

_____________________________

_____________________________

Legally Authorized Representative

LAR Signature

_______
Date

Name
Complete if the participant is not fluent in English and an interpreter was used to obtain
consent. Participants who do not read or understand English must not sign this full
consent form, but instead sign the short form translated into their native
language. This form should be signed by the investigator and interpreter only. If the
interpreter is affiliated with the study team, the signature of an impartial witness is also
required.
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Print name of interpreter: ______________________________________
Signature of interpreter: ___________________________________ Date: _________
An oral translation of this document was administered to the participant in
_____________ (state language) by an individual proficient in English and
____________ (state language).
Print name of impartial witness: __________________________________
Signature of impartial witness: ________________________________ Date:
_________

52

Appendix 2: Participant MACE Form
Definition of MACE
Major Adverse Cardiac Events including:
• Recurrent angina pain
• Development of heart failure
• Non-fatal infarction
• Presentation to the Emergency Department with cardiovascular-related illness
• Admission to the hospital for cardiovascular-related illness
• Percutaneous coronary intervention (PCI)
• Coronary artery bypass grafting (CABG)
• Stroke
• All-cause mortality
Over the past month, did participant number _______ experience…
Months
PostIntervention
MACE

1
mo

2mo

3mo

4mo

5mo

6mo

7mo

8mo

9mo

10mo

11mo

12mo

Total

Recurrent
angina pain
Heart
failure
Non-fatal
Infarction
ED
presentation
(CV related)
Hospital
Admission
(CV related)
PCI
Stroke
All-cause
mortality
Total

*Directions: Please fill in the participant identification number in the blank above.
Next, fill in which (if any) and how many MACE occur in the table above for each
participant then calculate the total number of MACE.
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Appendix 3: Sample Size Calculation
Sample Size based on a dichotomous variable using the Power and Sample Size
Calculator provided online by the Department of Biostatistics at Vanderbilt University
(https://vbiostatps.app.vumc.org/ps/).
-

Type I error (alpha) = 0.05
Power = 0.80 (beta = 0.20)
Probability of outcome for control participant = p0 = 2%
Probability of outcome for experimental participant = p1 = 11%
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